(UroToday.com) Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy has been shown to improve survival in patients with muscle-invasive bladder cancer. However, nearly 60% of patients are inherently resistant to neoadjuvant chemotherapy at the time of cystectomy. While several mechanisms of cellular resistance to cisplatin have been proposed, these do not offer any effective patient response prediction.